β受体阻滞剂在射血分数降低、中等及保留的心力衰竭患者中的疗效:双盲随机试验的个体患者水平分析
该研究基于11项双盲随机安慰剂对照试验的个体患者数据,按基线左室射血分数(LVEF)和心律分层,分析β受体阻滞剂对全因死亡和心血管死亡的影响。在窦性心律患者中,β受体阻滞剂可降低全因和心血管死亡,效果在LVEF<40%及40-49%亚组中一致,但在LVEF≥50%小亚组中未观察到获益;房颤患者中β受体阻滞剂未改善预后。
要点
- 窦性心律心衰患者中,β受体阻滞剂降低全因和心血管死亡,LVEF<40%证据最稳健。
- LVEF 40-49%窦性心律患者中,β受体阻滞剂组全因死亡7.2% vs 安慰剂12.4%,调整HR 0.59(95%CI 0.34-1.03)。
- 基线房颤患者中,β受体阻滞剂未改善预后。
核心结论
- 窦性心律且LVEF降低的心衰患者中,β受体阻滞剂改善LVEF和预后,LVEF<40%证据最稳健,LVEF 40-49%亚组观察到相似获益。
- 基线房颤患者中,β受体阻滞剂虽可提高LVEF(当基线LVEF<50%时),但未改善预后。
研究设计与样本
- 11项双盲、随机、安慰剂对照试验的个体患者数据荟萃分析,按基线LVEF和心律分层,采用意向性治疗分析。
- 共纳入窦性心律患者14 262例,中位LVEF 27%(四分位距21-33%),其中LVEF 40-49%者575例,LVEF≥50%者244例;基线房颤患者3050例。
主要发现
- 窦性心律患者中,β受体阻滞剂较安慰剂降低全因和心血管死亡,效果在LVEF分层间一致,但LVEF≥50%小亚组除外。
- LVEF 40-49%亚组中,β受体阻滞剂组全因死亡21/292[7.2%],安慰剂组35/283[12.4%],调整HR 0.59(95%CI 0.34-1.03)。
- LVEF 40-49%亚组中,心血管死亡β受体阻滞剂组13/292[4.5%],安慰剂组26/283[9.2%],调整HR 0.48(95%CI 0.24-0.97)。
- 中位随访1.0年(n=4601)后,窦性心律患者中除LVEF≥50%组外,β受体阻滞剂组LVEF均增加。
- 基线房颤患者中,β受体阻滞剂在基线LVEF<50%时提高LVEF,但未改善预后。
临床怎么用
- 对于窦性心律、LVEF降低(尤其是<40%)的心衰患者,β受体阻滞剂可改善LVEF和预后。
- 窦性心律、LVEF 40-49%的心衰患者可考虑使用β受体阻滞剂,但需注意证据强度弱于LVEF<40%者。
- 基线房颤的心衰患者使用β受体阻滞剂可能无法改善预后,决策需个体化。
局限性
- LVEF≥50%亚组样本量小(244例),结果解释需谨慎。
- 中位随访时间较短(1.3年),长期效果未充分评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Recent guidelines recommend that patients with heart failure and left ventricular ejection fraction (LVEF) 40-49% should be managed similar to LVEF ≥ 50%. We investigated the effect of beta-blockers according to LVEF in double-blind, randomized, placebo-controlled trials. METHODS AND RESULTS: Individual patient data meta-analysis of 11 trials, stratified by baseline LVEF and heart rhythm (Clinicaltrials.gov: NCT0083244; PROSPERO: CRD42014010012). Primary outcomes were all-cause mortality and cardiovascular death over 1.3 years median follow-up, with an intention-to-treat analysis. For 14 262 patients in sinus rhythm, median LVEF was 27% (interquartile range 21-33%), including 575 patients with LVEF 40-49% and 244 ≥ 50%. Beta-blockers reduced all-cause and cardiovascular mortality compared to placebo in sinus rhythm, an effect that was consistent across LVEF strata, except for those in the small subgroup with LVEF ≥ 50%. For LVEF 40-49%, death occurred in 21/292 [7.2%] randomized to beta-blockers compared to 35/283 [12.4%] with placebo; adjusted hazard ratio (HR) 0.59 [95% confidence interval (CI) 0.34-1.03]. Cardiovascular death occurred in 13/292 [4.5%] with beta-blockers and 26/283 [9.2%] with placebo; adjusted HR 0.48 (95% CI 0.24-0.97). Over a median of 1.0 years following randomization (n = 4601), LVEF increased with beta-blockers in all groups in sinus rhythm except LVEF ≥50%. For patients in atrial fibrillation at baseline (n = 3050), beta-blockers increased LVEF when < 50% at baseline, but did not improve prognosis. CONCLUSION: Beta-blockers improve LVEF and prognosis for patients with heart failure in sinus rhythm with a reduced LVEF. The data are most robust for LVEF < 40%, but similar benefit was observed in the subgroup of patients with LVEF 40-49%.
引用
- Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018. PMID: 29040525. doi:10.1093/eurheartj/ehx564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。